1. Home
  2. CLOV vs DBVT Comparison

CLOV vs DBVT Comparison

Compare CLOV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

HOLD

Current Price

$2.17

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$20.98

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLOV
DBVT
Founded
2014
2002
Country
United States
France
Employees
N/A
90
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
CLOV
DBVT
Price
$2.17
$20.98
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$2.90
$32.04
AVG Volume (30 Days)
5.1M
232.4K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
38.03
10.26
EPS
N/A
N/A
Revenue
$1,924,308,000.00
$5,636,000.00
Revenue This Year
$52.59
$79.21
Revenue Next Year
$15.37
$1,754.26
P/E Ratio
N/A
N/A
Revenue Growth
40.34
35.77
52 Week Low
$1.58
$7.53
52 Week High
$3.92
$26.19

Technical Indicators

Market Signals
Indicator
CLOV
DBVT
Relative Strength Index (RSI) 68.31 49.49
Support Level $2.12 $19.64
Resistance Level $2.25 $24.47
Average True Range (ATR) 0.10 1.17
MACD 0.05 0.12
Stochastic Oscillator 91.41 43.68

Price Performance

Historical Comparison
CLOV
DBVT

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: